pharma · Non-small Cell Lung Cancer · Epilepsy
Eisai
Eisai Co.,
NovaPharmaNews editorial coverage mentioning Eisai — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Tokyo, Japan, JP
- Employees
- 41
- Programs
- 22
- Drugs
- 31
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Eisai — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Eisai — regulatory, clinical, and market analysis.
Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
Biogen and Eisai have expanded LEQEMBI access in the U.S. with subcutaneous maintenance dosing, following FDA approval of the BLA in August 2025. The move could improve convenience, reduce infusion-related burden, and shape investor expectations for Eisai and Biogen stock.
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for generic eribulin mesylate injection. This approval offers a new therapeutic option for patients with pretreated metastatic breast cancer and unresectable or metastatic liposarcoma.
Eisai's Leqembi Sales Forecast: A Turning Point?
Structured plan for Eisai's Leqembi Sales Forecast: A Turning Point?
Eisai's Leqembi Sales Forecast: Projecting Blockbuster Status in Alzheimer's
Eisai projects significant growth for its Alzheimer's treatment, Leqembi, with sales forecasts indicating a strong path toward blockbuster status. This analysis explores the drivers behind this projection and its strategic implications for the pharmaceutical industry.